309 related articles for article (PubMed ID: 30583122)
1. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention.
Abrahamsen B; Skjødt MK; Vestergaard P
Bone; 2019 Mar; 120():476-481. PubMed ID: 30583122
[TBL] [Abstract][Full Text] [Related]
2. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
[TBL] [Abstract][Full Text] [Related]
3. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
4. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
6. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
[TBL] [Abstract][Full Text] [Related]
7. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
9. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006.
Abrahamsen B; Vestergaard P
Osteoporos Int; 2010 Mar; 21(3):373-80. PubMed ID: 19436931
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.
Fisher A; Martin J; Srikusalanukul W; Davis M
Clin Interv Aging; 2010 Nov; 5():355-62. PubMed ID: 21228901
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions.
Albert SG; Wood E
Endocr Pract; 2021 Nov; 27(11):1082-1092. PubMed ID: 34252583
[TBL] [Abstract][Full Text] [Related]
13. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality.
Sing CW; Lin TC; Bartholomew S; Bell JS; Bennett C; Beyene K; Bosco-Levy P; Bradbury BD; Chan AHY; Chandran M; Cooper C; de Ridder M; Doyon CY; Droz-Perroteau C; Ganesan G; Hartikainen S; Ilomaki J; Jeong HE; Kiel DP; Kubota K; Lai EC; Lange JL; Lewiecki EM; Lin J; Liu J; Maskell J; de Abreu MM; O'Kelly J; Ooba N; Pedersen AB; Prats-Uribe A; Prieto-Alhambra D; Qin SX; Shin JY; Sørensen HT; Tan KB; Thomas T; Tolppanen AM; Verhamme KMC; Wang GH; Watcharathanakij S; Wood SJ; Cheung CL; Wong ICK
J Bone Miner Res; 2023 Aug; 38(8):1064-1075. PubMed ID: 37118993
[TBL] [Abstract][Full Text] [Related]
14. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Kamata Y; Minota S
Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
[TBL] [Abstract][Full Text] [Related]
15. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
[TBL] [Abstract][Full Text] [Related]
16. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
Chau YT; Nashi N; Law LS; Goh RKH; Choo SX; Seetharaman SK
Arch Osteoporos; 2020 Sep; 15(1):141. PubMed ID: 32918196
[TBL] [Abstract][Full Text] [Related]
17. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.
Klop C; Gibson-Smith D; Elders PJ; Welsing PM; Leufkens HG; Harvey NC; Bijlsma JW; van Staa TP; de Vries F
Osteoporos Int; 2015 Jul; 26(7):1919-28. PubMed ID: 25963232
[TBL] [Abstract][Full Text] [Related]
18. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
Antonelli M; Einstadter D; Magrey M
J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
20. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
Vestergaard P; Schwartz F; Rejnmark L; Mosekilde L
Osteoporos Int; 2011 Mar; 22(3):993-1001. PubMed ID: 21165600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
